Blood and Marrow Transplant Group of Georgia
Atlanta, GA
Accepting patients
BMT CTN 2203
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
- JAK1 Inhibitor
- JAK2 Inhibitor
- Tyrosine Kinase (TK) Inhibitor
- Post-Allogeneic Stem Cell Transplant
- Randomization
- Phase 3